«Gaining FDA approval for new drug and
biologics licence applications [NDAs and BLAs] is becoming increasingly difficult and, in turn, there is an increased need for skilled regulatory affairs professionals, who can overcome such obstacles by developing innovative regulatory pathways to achieve market approval.»